Author

F. S. Dela Cruz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. L. Kung· 2 shared E. De Stanchina· 2 shared Y. Kuwahara· 2 shared A. Califano· 1 shared A. Heslin· 1 shared A. Kentsis· 1 shared A. R. Rainey· 1 shared A. Sweet-Cordero· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. L. Kung

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 30, 2023

FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy

S. Menon, D. Gracilla, M. R. Breese…·A. Tulpule

This study shows FET fusion oncoproteins disrupt DNA repair by inhibiting ATM signaling, making ATR inhibitors a potential therapy for FET rearranged cancers.

DOI 10.1101/2023.04.30.538578

humanDNA methylation

𝕏 PostBluesky

Cancer BiologybioRxivFeb 6, 2023

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Y. Kazansky, D. Cameron, H. S. Mueller…·A. Kentsis

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

DOI 10.1158/2159-8290.cd-23-0110

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 2, 2021

Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors - expanding patient-driven discovery beyond the Nof1.

L. J. Marks, D. Diolaiti, P. Mundi…·A. L. Kung

This study identifies XPO1 activation as a non-genetic vulnerability in malignant rhabdoid tumors using patient-driven discovery and validates selinexor as a potential therapeutic.

DOI 10.1101/2021.10.02.462793

humanbulk RNA-seq

𝕏 PostBluesky